Premium
Mucosal lesions in cutaneous lupus erythematosus successfully treated with hydroxychloroquine
Author(s) -
Kamaguchi Mayumi,
Iwata Hiroaki,
Asaka Takuya,
Shimizu Hiroshi,
Kitagawa Yoshimasa
Publication year - 2019
Publication title -
oral science international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.256
H-Index - 13
eISSN - 1881-4204
pISSN - 1348-8643
DOI - 10.1002/osi2.1006
Subject(s) - hydroxychloroquine , medicine , chloroquine , dermatology , cutaneous lupus erythematosus , systemic lupus erythematosus , autoimmune disease , lupus erythematosus , disease , immunology , pathology , malaria , covid-19 , infectious disease (medical specialty) , antibody
Cutaneous lupus erythematosus ( CLE ) is a rare, potentially disfiguring, chronic autoimmune disease with extremely variable skin and mucosal membrane manifestations. Hydroxychloroquine ( HCQ ) is an antimalarial drug that has been used in various countries to treat autoimmune diseases including CLE . HCQ was banned for a long time in Japan because of severe chloroquine retinopathy and was reapproved as a first‐line treatment for CLE in 2015. There are no case reports describing the effectiveness of HCQ for CLE with oral mucosal lesions in the dental field. We present a case of CLE whose oral lesions were successfully treated with HCQ .